Navigation Links
Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
Date:11/7/2008

the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials and potential efficacy of its products. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.


'/>"/>
SOURCE Transition Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Schering-Plough Announces Transition of Animal Health Leadership
2. ACS Signs $27 Million Contract with Alaska to Transition Fiscal Agent Services for State Medicaid Program
3. MidSouth eHealth Alliance to Transition to Commercial Software Solution from Informatics Corporation of America
4. Transition Therapeutics Announces No Material Change
5. Transitions Optical Offers Tips on How to Protect Eyes for Outdoor Sports Fans
6. Transition Therapeutics Announces Executive Management Appointments
7. AGA Medical Announces Management Transition
8. Booth Radiology Associates Chooses IDC To Complete Its Transition To Digital Imaging
9. GCI Successfully Transitions All Traffic to Galaxy 18 Satellite
10. Get the Facts on the Albuterol Inhaler Transition
11. AUDIO from Medialink and Transitions Optical: What You Cant See May Harm You
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3Haemonetics Sets Date for First Quarter Fiscal Year 2010 Earnings Release 3A August 3 2009 51439 1Varian Medical Systems Management to Present at the Piper Jaffray Cancer Summit 51436 1Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders Advises Frost 26 Sullivan 51431 1Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders Advises Frost 26 Sullivan 51431 2Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders Advises Frost 26 Sullivan 51431 3